Literature DB >> 15286456

Genetic association of CYP46 and risk for Alzheimer's disease.

Onofre Combarros1, Jon Infante, Javier Llorca, José Berciano.   

Abstract

An increasing number of studies suggest that cholesterol plays an important role in regulating beta-amyloid (Abeta) metabolism in Alzheimer's disease (AD). One of the most important mechanisms for the elimination of excess brain cholesterol is its conversion into the 24S-hydroxycholesterol catalyzed by cholesterol 24S-hydroxylase (CYP46). Preliminary evidence indicates that an intron 2 CYP46 T/C gene polymorphismis associated with increased brain Abeta load and higher risk of AD. A case-control study utilizing a clinically well-defined group of 321 sporadic AD patients and 315 control subjects was performed to test this association. Our results indicate that the intron 2 CYP46 C/C genotype may predispose to AD, and this association is independent of the apolipoprotein E genotype. 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286456     DOI: 10.1159/000080025

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

Review 1.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary.

Authors:  Anna Juhász; Agnes Rimanóczy; Krisztina Boda; Gábor Vincze; Gyozo Szlávik; Marianna Zana; Annamária Bjelik; Magdolna Pákáski; Nikoletta Bódi; András Palotás; Zoltán Janka; János Kálmán
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

3.  A pilot study of gene/gene and gene/environment interactions in Alzheimer disease.

Authors:  Nader Ghebranious; Bickol Mukesh; Philip F Giampietro; Ingrid Glurich; Susan F Mickel; Stephen C Waring; Catherine A McCarty
Journal:  Clin Med Res       Date:  2010-08-03

4.  An intronic CYP46A1 polymorphism is associated with Alzheimer disease in a Chinese Han population.

Authors:  Xiao-ming He; Zhen-xin Zhang; Jun-Wu Zhang; Yong-tao Zhou; Cheng-bin Wu; Mou-ni Tang; Zhen Hong
Journal:  J Mol Neurosci       Date:  2012-04-22       Impact factor: 3.444

Review 5.  CYP46A1 T/C polymorphism associated with the APOE ε4 allele increases the risk of Alzheimer's disease.

Authors:  Ling Li; Zegang Yin; Juan Liu; Gongbo Li; Yanjiang Wang; Jiachuan Yan; Huadong Zhou
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

Review 6.  Cyp46 polymorphisms in Alzheimer's disease: a review.

Authors:  Anália Nusya Medeiros Garcia; Maria Tereza Cartaxo Muniz; Hugo Rafael Souza e Silva; Helker Albuquerque da Silva; Luiz Athayde-Junior
Journal:  J Mol Neurosci       Date:  2009-08-25       Impact factor: 3.444

Review 7.  Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis.

Authors:  M Maulik; D Westaway; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

8.  Role of cholesterol 24S-hydroxylase gene polymorphism (rs754203) in primary open angle glaucoma.

Authors:  Georg Mossböck; Martin Weger; Christoph Faschinger; Otto Schmut; Wilfried Renner; Andreas Wedrich; Christina Zimmermann; Yosuf El-Shabrawi
Journal:  Mol Vis       Date:  2011-02-26       Impact factor: 2.367

9.  Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.

Authors:  Toshiya Nishi; Shinichi Kondo; Maki Miyamoto; Sayuri Watanabe; Shigeo Hasegawa; Shigeru Kondo; Jason Yano; Etsurou Watanabe; Tsuyoshi Ishi; Masato Yoshikawa; Haruhi Kamisaki Ando; William Farnaby; Shinji Fujimoto; Eiji Sunahara; Momoko Ohori; Matthew J During; Takanobu Kuroita; Tatsuki Koike
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.